Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVER: Silymarin for Drug-induced Elevated Liver Enzymes
NCT05144217Phase 3Completed
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of silymarin in drug induced liver injury (DILI) (4 arms). Primary endpoint: Alanine Aminotransferase at Day 35. Started Jun 2021; status: completed.
02
Drugs
silymarin
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT05144217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144217.